New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review
Journal of Clinical Medicine · 13.02.2024 · 13 (4) · 1065
DOI: 10.3390/jcm13041065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.02.2024. Verfasst von Alexandru Dinulescu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
Osteogenesis imperfecta (OI) is a rare skeletal dysplasia characterized as a heterogeneous disorder group with well-defined phenotypic and genetic features that share uncommon bone fragility. The current treatment options, medical and orthopedic, are limited and not efficient enough to improve the low bone density, bone fragility, growth, and mobility of the affected individuals, creating the need for alternative therapeutic agents. (2)
Methods
We searched the medical database to find papers regarding treatments for OI other than conventional ones. We included 45 publications. (3)
Results
In reviewing the literature, eight new potential therapies for OI were identified, proving promising results in cells and animal models or in human practice, but further research is still needed. Bone marrow transplantation is a promising therapy in mice, adults, and children, decreasing the fracture rate with a beneficial effect on structural bone proprieties. Anti-RANKL antibodies generated controversial results related to the therapy schedule, from no change in the fracture rate to improvement in the bone mineral density resorption markers and bone formation, but with adverse effects related to hypercalcemia. Sclerostin inhibitors in murine models demonstrated an increase in the bone formation rate and trabecular cortical bone mass, and a few human studies showed an increase in biomarkers and BMD and the downregulation of resorption markers. Recombinant human parathormone and TGF-β generated good results in human studies by increasing BMD, depending on the type of OI. Gene therapy, 4-phenylbutiric acid, and inhibition of eIF2α phosphatase enzymes have only been studied in cell cultures and animal models, with promising results. (4)
Conclusions
This paper focuses on eight potential therapies for OI, but there is not yet enough data for a new, generally accepted treatment. Most of them showed promising results, but further research is needed, especially in the pediatric field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departament of Pediatrics and Department of Pediatric Orthopedics, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children ''Grigore Alexandrescu'', 011743 Bucharest, Romania.
ORCID-Profile: Alexandru Dinulescu, Irina Dijmărescu, Daniela Păcurar, Alexandru Ulici
Zitieren
APA
Dinulescu, A., Păsărică, A. S., Carp, M., Dușcă, A., Dijmărescu, I., Pavelescu, M. L., Păcurar, D., & Ulici, A. (2024). New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review. Journal of Clinical Medicine, 13(4), 1065. https://doi.org/10.3390/jcm13041065
Vancouver
Dinulescu A, Păsărică AS, Carp M, Dușcă A, Dijmărescu I, Pavelescu ML, et al. New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review. Journal of Clinical Medicine. 2024;13(4):1065. doi:10.3390/jcm13041065
BibTeX
@article{Dinulescu2024,
author = {Dinulescu, Alexandru and Păsărică, Alexandru-Sorin and Carp, Mădălina and Dușcă, Andrei and Dijmărescu, Irina and Pavelescu, Mirela Luminița and Păcurar, Daniela and Ulici, Alexandru},
title = {New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {4},
pages = {1065},
doi = {10.3390/jcm13041065}
}
EUVIMED